Internal Medicine Department Pfizer Hellas, Neo Psychiko, 243 Mesogeion Avenue, Athens, SA, 15451, Greece.
2nd Orthopedic Department, KAT General Hospital of Attica, Athens, Greece.
BMC Musculoskelet Disord. 2023 Aug 15;24(1):651. doi: 10.1186/s12891-023-06770-7.
Osteoarthritis (OA) represents a leading cause of disability with limited data available for the Greek patients.
To evaluate the impact of moderate to severe symptomatic hip/knee OA under treatment on physical performance and quality of life.
A non-interventional, cross-sectional, epidemiological study of patients with moderate/severe OA, recruited in a single visit from 9 expert sites in Athens, Greece. Assessments were based on commonly used outcome scales: the Hip disability and Osteoarthritis Outcome Score (HOOS), the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the EuroQol-5-Dimensions 3-levels questionnaire (EQ-5D-3L).
One hundred sixty-four patients were included in the analysis. Most of the patients were females (78.7%), with a mean age of 70.5 ± 10.2 years. Comorbidities were reported by 87.2% of patients with hypertension being the most frequently reported (53.7%), followed by dyslipidemia (31.1%), obesity (24.4%) and diabetes mellitus (23.2%). Paracetamol was the most common treatment (96%), followed by NSAIDs (75%), opioids (50%) and locally applied medications (42.7%). Both hip and knee OA patients showed substantial deterioration in health-related quality of life (QoL) and health status as reflected by the HOOS/KOOS (Function in sport and recreation was the most impaired subscale, followed by Hip- or Knee-related QoL). The mean EQ-5D-3L index score was 0.396 ± 0.319 and the mean EQ-VAS score was 52.1 ± 1.9. When compared indirectly to the local population norms our OA population had worse QoL indices.
Our findings suggest the functional disability and impaired QoL of Greek patients with moderate/severe hip/knee OA under treatment emphasizing the need for novel treatments that will reduce the burden of the disease.
骨关节炎(OA)是导致残疾的主要原因,而针对希腊患者的数据有限。
评估接受治疗的中重度症状性髋/膝关节 OA 对身体机能和生活质量的影响。
在希腊雅典的 9 个专家地点,进行了一项非干预性、横断面、流行病学研究,招募了中/重度 OA 患者进行单次就诊。评估基于常用的结局量表:髋关节残疾和骨关节炎结局评分(HOOS)、膝关节损伤和骨关节炎结局评分(KOOS)以及欧洲五维健康量表 3 级问卷(EQ-5D-3L)。
共纳入 164 例患者进行分析。大多数患者为女性(78.7%),平均年龄为 70.5±10.2 岁。87.2%的患者报告有合并症,其中高血压最常见(53.7%),其次为血脂异常(31.1%)、肥胖(24.4%)和糖尿病(23.2%)。最常用的治疗药物是对乙酰氨基酚(96%),其次是非甾体抗炎药(75%)、阿片类药物(50%)和局部应用药物(42.7%)。髋膝关节 OA 患者的健康相关生活质量(QoL)和健康状况均明显恶化,HOOS/KOOS 评分结果显示(运动和娱乐功能是受损害最严重的亚量表,其次是髋或膝关节相关 QoL)。平均 EQ-5D-3L 指数评分为 0.396±0.319,平均 EQ-VAS 评分为 52.1±1.9。与当地人群的标准进行间接比较,我们的 OA 患者的 QoL 指数更差。
我们的研究结果表明,接受治疗的希腊中重度髋/膝关节 OA 患者存在功能障碍和 QoL 受损,这强调了需要新型治疗方法来减轻疾病负担。